Gerresheimer cuts 2026 outlook after weak 2025 results, shares slide on Xetra

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 14:45.

Gerresheimer (DE000A0LD6E6) reset expectations on Monday with audited 2025 figures, a lower 2026 outlook and a suspended dividend, while the shares trade clearly weaker on Xetra. The move follows an internal investigation into revenue recognition and fresh guidance published via an ad-hoc statement in Düsseldorf this morning.EQS ad-hoc release from Gerresheimer

What the new figures show

For the 2025 financial year Gerresheimer reported revenue of around 2.32 billion euros, below analyst expectations of about 2.39 billion euros compiled by Vara Research, and adjusted EBITDA of 384 million euros versus a roughly 470 million euro consensus, according to Investing.com.Investing.com commentary on Gerresheimer results The company swung to a consolidated net loss of 318.7 million euros after booking around 521.5 million euros of non-cash impairments and roughly 71.8 million euros in restructuring and other exceptional charges in 2025.Investing.com commentary on Gerresheimer results

Management also decided not to pay a dividend for 2025, compared with analyst expectations for a payout of about 0.34 euros per share, as it prioritizes balance sheet strength and restructuring measures.Investing.com commentary on Gerresheimer results The audited annual and consolidated financial statements, delayed by the internal investigation into bill-and-hold revenue recognition and broader accounting practices in 2024 and 2025, were scheduled for publication by noon CEST on June 29, 2026, according to the company’s ad-hoc disclosure.EQS ad-hoc release from Gerresheimer

Lowered 2026 guidance and sector context

Looking ahead to 2026, Gerresheimer now guides for revenue at the lower half of its previously communicated 2.3 to 2.4 billion euro range and an adjusted EBITDA margin of 17 to 18 percent, down from 18 to 19 percent, reflecting project delays, ramp-up issues and a tougher macro backdrop.Investing.com note on outlook change Free cash flow is now expected between minus 50 million and minus 100 million euros rather than the previously guided moderately positive figure, underscoring the near-term financial pressure from investments and restructuring.EQS ad-hoc release from Gerresheimer

Within European pharmaceutical packaging, peers such as Schott Pharma are also being watched as investors compare demand trends for injectable drug packaging and capacity expansion plans across the sector.Investing.com sector comparison Gerresheimer highlights ongoing strategic steps such as the planned sale of its U.S. unit Centor and a comprehensive debt refinancing, both targeted for completion before the end of the 2026 financial year, to refocus the portfolio and stabilize funding.Investing.com commentary on strategy measures

How Gerresheimer earns its money

Gerresheimer generates most of its revenue from specialty glass and plastic packaging for the pharmaceutical and biotech industries, including vials, prefillable syringes, ampoules and drug-delivery systems such as inhalers and insulin pens, supplied to large customers in Europe, North America and emerging markets.Company overview of business units The group’s portfolio also covers diagnostic and medical technology components, with a focus on long-term supply contracts and high regulatory requirements that support recurring revenue streams.

Where the shares trade today

The Gerresheimer shares (DE000A0LD6E6) trade on Xetra at 25.04 euros as of 2026-06-29, 12:50, with the stock showing a daily decline of around 2.9 percent on that platform while the Stuttgart listing recently showed 24.76 euros, according to exchange data.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. All information is based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, seek professional advice before making investment decisions.